摘要：

Preclinical 1. Mitomycin C is an alkylating agent requiring reduction of the quinone to be active. 2. The aziridine ring is essential for the antitumor activity of mitomycin C. 3. The degree of DNA cross-linking and tumor inhibition is proportional to the guanine and cytosine content of the DNA. 4. Mitomycin C has no significant direct effects on RNA. 5. Early G 1 and S phases are most sensitive, while G 2 is less sensitive to the action of mitomycin C. 6. Mitomycin C is absorbed orally, but requires 8 to 12 times the IV dose for equivalent activity. 7. Mitomycin C is well absorbed intraperitoneally and intramuscularly, but is only minimally absorbed when given by intravesicular administration. 8. Mitomycin C is rapidly cleared from serum primarily by metabolism in the liver. 9. Intermittent dosage schedules are predicted to be better on the basis of pharmacokinetic and cytopathologic studies. 10. Mitomycin C is active against a broad spectrum of bacteria, viruses, rickettsiae and tumors. 11. The major toxicity in animals and man is myelosuppression. This reaction is delayed and cumulative. 12. Glomerular damage leading to renal failure is an unusual toxicity of mitomycin C. 13. Mitomycin C is carcinogenic in several species of rodents. 1. Mitomycin C appears to be active in: a. adenocarcinoma of the stomach b. adenocarcinoma of the pancreas c. adenocarcinoma of the colon d. adenocarcinoma of the breast e. certain head and neck cancers f. chronic myelogenous leukemia. 2. Mitomycin C may be active in: a. bilary carcinomas b. squamous cell carcinoma of the cervix c. ovarian carcinomas d. carcinoma of the lung. 3. Mitomycin C is probably not active in: a. osteogenic sarcomas b. multiple myeloma. 4. Mitomycin C results in remissions of short duration. 5. Severe hematopoietic toxicities occur in a high percentage of patients treated with mitomycin C. 6. Intermittent dosage schedules are probably best. 7. Mitomycin C in combination with other drugs may be of benefit in selected cancers. 8. The role of mitomycin C as a surgical or radiotherapeutic adjuvant is unclear. 9. Intravesicular instillation of mitomycin C may be of value in the treatment of transitional cell carcinoma of the bladder. 10. Tumors resistant to other alkylating agents are frequently sensitive to Mitomycin C.

展开